Mounjaro®
Starting from £179.99/mo
Start journey Learn moreRybelsus vs Wegovy tablets vs Wegovy injection: making the right call for weight management
The decision most people don't know they're making
When someone searches for oral semaglutide to lose weight, they often land on Rybelsus because it appears first in results. That happens for a simple reason: Rybelsus has been available in the UK since 2020, while Wegovy tablets only received MHRA approval in mid-2026. The molecules are identical. The licensed uses are not.
Rybelsus comes in 3 mg, 7 mg and 14 mg tablets, doses calibrated for blood glucose control in adults with type 2 diabetes, not for the appetite and weight-reduction programme that Wegovy tablets follow. Wegovy tablets escalate through 1.5 mg, 4 mg, 9 mg and up to a 25 mg maintenance dose. That higher dose range is what the weight-loss trial evidence is built on. Using the wrong product means using doses and a titration schedule designed for a different condition entirely, assessed by the MHRA under a different indication. As the NHS semaglutide page explains, these are distinct medicines in UK licensing terms despite sharing an active ingredient.
The real decision, then, is not which online seller to use. It is whether your situation calls for a weight-management medicine at all, and if so, which licensed option suits your health profile. That is precisely the kind of question a prescriber resolves, not a product comparison page, and not a checkout screen.
How Wegovy tablets compare with the Wegovy injection and Mounjaro
Once you are looking at the right products for weight management, there are three licensed injectable or oral options available privately in the UK: Wegovy tablets (oral semaglutide), Wegovy injection (weekly semaglutide 2.4 mg, with a 7.2 mg pen now approved), and Mounjaro (tirzepatide, a dual GIP and GLP-1 receptor agonist). The table below sets out the factual comparison, using figures from the MHRA and published clinical trials.
| Feature | Rybelsus | Wegovy tablets | Wegovy injection | Mounjaro (tirzepatide) |
|---|---|---|---|---|
| UK weight-loss licence | No, type 2 diabetes only | Yes (MHRA, June 2026) | Yes | Yes |
| How taken | Once-daily tablet | Once-daily tablet | Weekly injection | Weekly injection |
| Maintenance dose | Up to 14 mg (diabetes) | Up to 25 mg | 2.4 mg or 7.2 mg | Up to 15 mg |
| Average weight loss (trial) | Not assessed for weight loss | ~13.6% (OASIS 4, 64 weeks) [Source: MHRA/Novo Nordisk, June 2026] | ~15% at 2.4 mg (STEP 1, 68 weeks) [Source: NEJM] | ~20–21% at 15 mg (SURMOUNT-1, 72 weeks) [Source: NEJM] |
| Storage | Room temperature | Room temperature | Refrigerated | Refrigerated |
| Dispensed by nume for weight loss | No | Yes | Yes | Yes |
The trial figures carry a necessary caveat: different study populations, different durations, no direct head-to-head between Wegovy tablets and the injections. The ~13.6% average for oral semaglutide rose to around 17% among participants who stuck fully to treatment in OASIS 4, but that fully-adherent figure should not be quoted as if it were the plain average. For anyone who prefers a tablet to a needle, you can explore the oral semaglutide options available to UK adults in more detail separately.
Why the supply route matters more than the product name
A question our prescribers hear fairly often: if Rybelsus and Wegovy tablets are the same molecule, can I just take Rybelsus at a higher dose? The answer is no, for two reasons. First, the licensed dose ceiling for Rybelsus is 14 mg, well below the 25 mg maintenance dose in the Wegovy weight-loss programme. Second, using a medicine outside its licensed indication is an off-label decision that belongs to a supervising clinician, not to a patient browsing options online.
The supply-route question also has a safety dimension. Semaglutide is a prescription-only medicine, and if you want to buy semaglutide tablets legally in the UK, you need a valid prescription issued after a proper clinical assessment. The MHRA has issued repeated warnings about fake and illegally sold weight-loss medicines, including pens found to contain insulin rather than semaglutide. A product described as Rybelsus sold by an unverified online source is a counterfeit risk, not a budget alternative.
A pharmacy you can verify on the GPhC register before you hand over any details is the baseline check. nume's GPhC premises registration is 9012878. Every order is assessed by a named GPhC-registered Independent Prescriber on the day it arrives, not queued for automated approval. If you want to understand more about how the consultation works, the FAQs cover the process in plain terms, or you can read about the clinical team on the prescriber profile page.
What licensed weight-loss treatment actually looks like through a regulated pharmacy
If you submitted your consultation before midday on a weekday, your prescriber reviews it the same day. Think of it as getting an answer before the school run, your case is not sitting in a queue overnight. Once approved, the medicine is dispatched the same day and arrives the next working day via DPD, in plain packaging. No subscription is set up without your knowledge; every repeat order is reviewed again before anything is sent.
For weight management specifically, the licensed oral option is Wegovy tablets, and the licensed injectable options are Wegovy and Mounjaro. The GPhC-registered pharmacy route for oral semaglutide is straightforward once you know what you are looking for. If you are undecided between a tablet and an injection, the treatment overview sets out the practical differences, and the individual product pages go into the specifics of each dose stage. Which option suits your health profile is a clinical decision our prescribers make with you, not one this page can make for you.
If you are ready to find out whether you are eligible, the free consultation is the place to start. There is no charge to find out.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.